Clinical Efficacy of Recombinant Activated Factor VII in Management of Postpartum Hemorrhage.
10.14734/kjp.2013.24.1.29
- Author:
Soo Hyeon MOON
1
;
Seung Chul KIM
;
Jong Kil JOO
;
Dong Soo SUH
;
Dong Hyung LEE
Author Information
1. Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan, Korea. ksch0127@naver.com
- Publication Type:Original Article
- Keywords:
Clinical efficacy;
Postpartum hemorrhage;
Recombinant activated factor VII
- MeSH:
Factor VIIa;
Fibrinogen;
Hemorrhage;
Humans;
International Normalized Ratio;
Outcome Assessment (Health Care);
Postpartum Hemorrhage;
Postpartum Period;
Recombinant Proteins;
Retrospective Studies
- From:Korean Journal of Perinatology
2013;24(1):29-36
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was aimed to investigate the clinical efficacy of recombinant activated factor VII (rFVIIa) for patients with intractable postpartum hemorrhage. METHODS: This was a retrospective study of ten patients who were treated with rFVIIa from July 2010 to February 2012 in one tertiary center. To evaluate each case, we used a standardized case record form. The primary outcome measures were response of rFVIIa, reduction of blood product requirement, changes of coagulation parameter. The response of rFVIIa was categorized to three groups: "complete responder", "partial responder", "poor responder". RESULTS: After the administration of rFVIIa, effect for bleeding was completely responded in 4 patients, partially responded in 6 patients, and poorly responded in none. A certain amount of reduction in blood product requirements was noted following rFVIIa administration, although no significant differences were observed statistically between before and after rFVIIa administration except RBC (P<0.01). Fibrinogen and INR were significantly reduced in all case types, but other coagulation parameters were not (P<0.01). CONCLUSION: The present results suggest that rFVIIa is a beneficial therapeutic option that could reduce blood loss and contribute to reduction of maternal morbidities and mortalities in patients with massive postpartum hemorrhage.
